Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cognition Therapeutics Inc
(NQ:
CGTX
)
0.7100
+0.0680 (+10.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cognition Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
August 08, 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
August 08, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
August 05, 2024
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 30, 2024
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!
Via
InvestorPlace
A Preview Of Cognition Therapeutics's Earnings
March 25, 2024
Via
Benzinga
Dow Edges Lower; Ventyx Biosciences Shares Plummet
July 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 29, 2024
Via
Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
July 29, 2024
Via
Benzinga
Exposures
Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
July 29, 2024
Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units.
Via
InvestorPlace
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
July 29, 2024
Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional...
Via
Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
July 29, 2024
NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem.
Via
InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
July 29, 2024
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.
Via
InvestorPlace
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
July 29, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 29, 2024
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!
Via
InvestorPlace
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
July 29, 2024
Via
Benzinga
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
July 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 22, 2024
Via
Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 21, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
May 07, 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
April 29, 2024
- Top-line Results Expected in the Second Half of 2024 -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 22, 2024
Via
Benzinga
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023
March 26, 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 26, 2024
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.